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Résumé en
anglais
CONTEXT: Strontium ranelate reduces vertebral and nonvertebral fracture risk in
postmenopausal osteoporosis.
OBJECTIVE: The objective of this study was to determine the efficacy and safety
of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1
year).
DESIGN: This was an international, unbalanced (2:1), double-blind, randomized
placebo-controlled trial (MALEO [MALE Osteoporosis]).
SETTING: This international study included 54 centers in 14 countries.
PARTICIPANTS: PARTICIPANTS were 261 white men with primary osteoporosis.
INTERVENTION: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was
administered.
MAIN OUTCOME MEASURES: Lumbar spine (L2-L4), femoral neck, and total hip
bone mineral density (BMD), biochemical bone markers, and safety were
measured.
RESULTS: Baseline characteristics were similar in both groups in the whole
population (age, 72.9 ± 6.0 years; lumbar spine BMD T-score, -2.7 ± 1.0; femoral
neck BMD T-score, -2.3 ± 0.7). Men who received strontium ranelate over 2 years
had greater increases in lumbar spine BMD than those who received placebo
(relative change from baseline to end, 9.7% ± 7.5% vs 2.0% ± 5.5%; between-
group difference estimate (SE), 7.7% (0.9%); 95% confidence interval, 5.9%-9.5%;
P < .001). There were also significant between-group differences in relative
changes in femoral neck BMD (P < .001) and total hip BMD (P < .001). At the end
of treatment, mean levels of serum cross-linked telopeptides of type I collagen, a
marker of bone resorption, were increased in both the strontium ranelate group
(10.7% ± 58.0%; P = .022) and the placebo group (34.9% ± 65.8%; P < .001). The
corresponding mean changes of bone alkaline phosphatase, a marker of bone
formation, were 6.4% ± 28.5% (P = .005) and 1.9% ± 25.4% (P = .505),
respectively. After 2 years, the blood strontium level (129 ± 66 μmol/L) was similar
to that in trials of postmenopausal osteoporosis. Strontium ranelate was generally
well tolerated.
CONCLUSIONS: The effects of strontium ranelate on BMD in osteoporotic men
were similar to those in postmenopausal osteoporotic women, supporting its use in
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